First Drug for Rare Inflammation Syndrome Approved by FDA
The FDA has approved the first drug for the treatment of a rare condition in…
The FDA has approved the first drug for the treatment of a rare condition in…
Sobi will enter the clinic after the Investigational New Drug application for its rare metabolic…
The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but…
Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy…
Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights…
The Hemophilia Aid Program has just touched down the first batch of treatments in its…
Welcome in our Top of the week list! This week is full of uncommon stories.…